CVS Caremark moved to place Lilly’s oral obesity drug Foundayo on its formularies starting June 1, while adding back Zepbound as a preferred option starting Oct. 1. Novo Nordisk’s Wegovy pill and injection were retained as preferred, meaning both companies now hold preferred coverage positions across CVS’s largest commercial payer channel. The decision is expected to expand access and shift the competitive balance in the U.S. GLP-1 and obesity drug market, reversing an earlier advantage Novo gained through a CVS formulary arrangement. Analysts said the change increases the addressable pool for Lilly’s two products and improves market reach for employers using CVS Caremark.